The latest buyout buzz focuses on a small UK biotech spinout working on a new drug for women’s health.
Details are few and far between, but the company has a potential hormone replacement therapy called NT-814 that would fit the profile for Allergan’s BD team.
NeRRe Therapeutics, which spun out of GSK taking some unwanted programs in neurosciences, split off the women’s health biotech a few months ago.
KaNDy took a neurokinin-1,3 receptor antagonist — with potential as a hormone replacement therapy — with plans to take it into a Phase IIb study for postmenopausal vasomotor symptoms.
That would give Allergan some human data to look at as it beefs up that section of the pipeline, if a deal is completed.
KaNDy Therapeutics is led by managing director Mary Kerr and chaired by Iain Dukes, a venture partner at OrbiMed Advisors. The company is based at the Stevenage Bioscience Catalyst in the UK.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,400+ biopharma pros who read Endpoints News by email every day.Free Subscription